Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Received: 30 October 2021
Revised: 3 February 2022
Accepted: 3 February 2022
First Online: 7 March 2022
: J. Fiehler is a consultant for Acandis, Boehringer Ingelheim, Codman, Microvention, Sequent, Stryker; a speaker for Bayer Healthcare, Bracco, Covidien/ev3, Penumbra, Philips, Siemens; received grants from Bundesministerium für Wirtschaft und Energie (BMWi), Bundesministerium für Bildung und Forschung (BMBF), Deutsche Forschungsgemeinschaft (DFG), European Union (EU), Covidien, Stryker (THRILL study), Microvention (ERASER study), Philips. G. Thomalla received reports grant support and lecture fees from Bayer, personal fees from Acandis, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, Portola, and Stryker. All other authors report no disclosures.
: This multi-center retrospective study was approved by the Ethics Committee of the University of Hamburg and the Hamburg Chamber of Physicians, Hamburg, Germany, and the Ethics Committee of the University of Muenster and the Westfalian Chamber of Physicians, Muenster, Germany, and written informed consent was waived by the institutional review boards. All study protocols and procedures were conducted in accordance with the Declaration of Helsinki.